Kiora Pharmaceuticals (KPRX) EBITDA Margin (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly EBITDA Margin came in at 82.64% in Q1 2024, up 100.85% on a QoQ basis from 9698.8% in Q4 2020.

Kiora Pharmaceuticals (KPRX) EBITDA Margin (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has 6 years of EBITDA Margin data on file, last reported at 82.64% in Q1 2024.

Quarterly EBITDA Margin changed N/A year-over-year to 82.64% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 28.19% (changed N/A YoY) and the FY2024 annual result came in at 28.19%, changed N/A from the prior year.
EBITDA Margin climbed to 82.64% in Q1 2024, from 9698.8% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 82.64% in Q1 2024 to a low of 9698.8% in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Kiora Pharmaceuticals	16.25 Mn	16.25 Mn	-	-

Download Data